Safinamide improves motor symptoms severity and daily living in Parkinson’s Disease (PD) patients
Objective: To evaluate the clinical effects of safinamide, administered as add-on therapy to levodopa in fluctuating PD patients, on symptoms severity and daily living. Background:…Effects of safinamide and rasagiline on in vivo glutamate release in 6-OHDA hemilesioned rats
Objective: To investigate the effects of safinamide (saf) and rasagiline on in vivo glutamate (Glu) release in the 6-hydroxydopamine (6-OHDA) hemilesioned rat model of Parkinson’s…Safinamide reduces membrane excitability and synaptic transmission of striatal spiny projection neurons in a rat model of Parkinson’s disease
Objective: The effect of safinamide (saf) on the electrical membrane properties and both excitatory and inhibitory synaptic transmission of striatal spiny projection neurons (SPNs) was…Neural plasticity based on the change of the glutamate receptors: Repetition of electrical stimulation for the reduction of Parkinsonian symptoms
Objective: This study investigated the fundamental mechanism how the repeated electrical stimulation (ES) affects the reduction of parkinsonian symptoms. Background: The reduced parkinsonian symptoms by…Change of extracellular glutamate and GABA level in striatum during deep brain stimulation of the entopeduncular nucleus in rats
Objective: Globus pallidus interna (GPi) is recognized as an effective treatment for advanced Parkinson’s disease. However, the neurochemical basis of its effects remains unknown. The…Relationship between symptoms and regional density of metabotropic glutamate receptors subtype 1 measured with 11C-ITMM PET in de novo Parkinson’s disease
Objective: To investigate correlations of motor and non-motor symptoms with the brain densitiesof the metabotropic glutamate receptor subtype 1 (mGluR1) in de novo Parkinson’s disease…Safinamide inhibition of in vivo glutamate release in a rat model of Parkinson’s Disease
Objective: To evaluate whether safinamide inhibits in vivo glutamate (Glu) release in a rodent model of Parkinson’s disease (PD), i.e. the 6-hydroxydopamine (6-OHDA) hemilesioned rat.…A novel mGlu4 PAM alleviates motor symptoms in primate models of PD and of LID
Objective: Objective was to assess the therapeutic potential of our novel mGlu4 positive allosteric modulator (PAM), foliglurax, as an anti-parkinsonian treatment in gold-standard primate models.…Use of safinamide: A clinical practice review of 2 year experience
Objective: Review the clinical use, efectivity and side efects in a population based cohort. Background: Safinamide is an oral, once a day adjunctive therapy for…Ocular motor function in stiff person syndrome – Role of GABA and beyond
Objective: Delineate pathophysiology of gaze-holding function in stiff person syndrome (SPS). Background: Glutamic acid decarboxylase (GAD) catalyzes conversion of glutamate to gamma-aminobutyric acid (GABA). Anti-GAD…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.